GeoVax Labs, Inc. (Nasdaq: GOVX) reported financial results for the second quarter of 2026, highlighting continued progress toward the planned initiation of a pivotal immunobridging study for its GEO-MVA vaccine candidate. The company is pursuing an expedited regulatory pathway established through Scientific Advice discussions with the European Medicines Agency (EMA).
During the quarter, GeoVax advanced clinical operations planning, start-up activities, and manufacturing preparedness. The company has previously manufactured and released cGMP clinical trial material and is advancing its AGE1 continuous cell-line manufacturing platform for future commercial-scale production. GEO-MVA is designed to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.
David A. Dodd, Chairman and CEO of GeoVax, stated: "During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study. Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply."
In addition to GEO-MVA, GeoVax continues to advance Gedeptin, its investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism may complement PD-1-based therapies by improving responsiveness in immunologically resistant tumors. GeoVax holds an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4,426,578 for the three months ended June 30, 2026, compared to $5,369,783 in the same period in 2025. Revenue from government contracts was $0 in Q2 2026, versus $852,282 in Q2 2025, due to the termination of the BARDA contract for the GEO-CM04S1 COVID-19 vaccine program in April 2025. Research and development expenses decreased to $3,110,508 from $4,728,998, primarily reflecting lower costs associated with discontinued COVID-19 activities. General and administrative expenses declined to $1,331,564 from $1,542,190. Cash and cash equivalents stood at approximately $3.1 million as of June 30, 2026.
The company's strategic reprioritization, announced in May 2026, concentrates resources on GEO-MVA and Gedeptin, reflecting clearer regulatory pathways and stronger demand visibility. The decision to discontinue active development of GEO-CM04S1 was not related to safety or efficacy concerns but rather the evolution of the global COVID-19 vaccine market. GeoVax is engaging with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
More details are available in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. For further information, visit www.geovax.com.
